Advances in Pharmacy-Led Delivery and Access Models for Strengthening Primary Healthcare Systems and Expanding Medicine Availability in Emerging Markets

point for the proposition that multifaceted interventions outperform single component approaches (Chuc et al., 2002). Across developing Southeast Asia more broadly, community pharmacies have been progressively drawn into public health initiatives spanning health promotion, infectious disease control, and chronic disease management, though usually through pilots that struggle to achieve institutional permanence (Hermansyah et al., 2016). In low- and middle-income Asian settings generally, the performance of retail pharmacies varies widely across ownership structures and regulatory environments, cautioning against the assumption that any single organizational form guarantees quality (Miller & Goodman, 2016). Read together, these experiences support several cross-cutting lessons. First, engagement outperforms prohibition: every documented success involves working with the existing retail layer rather than attempting to suppress it. Second, multifaceted interventions outperform single levers, a conclusion reinforced by comprehensive review evidence on interventions with informal private providers, which finds that training reliably improves knowledge, that effects on practice are stronger when training is combined with supervision, incentives, and regulatory measures, and that sustainability remains the weakest link (Shah, Brieger, & Peters, 2011). Third, commercial viability is a design constraint, not an afterthought: accreditation and upgrading survive only where compliant outlets remain profitable. Fourth, institutional anchoring matters: programs embedded in ministries, local governments, and professional associations outlast donor funded pilots. 6. Financing Pharmacy-Based Access: Prepayment, Purchasing, and Targeted Subsidies Availability without affordability does not constitute access. Because retail pharmaceutical markets in emerging economies are financed overwhelmingly out of pocket, the financing question determines whether the availability gains generated by pharmacy-led models translate into utilization, adherence, and health outcomes. Medicines are a leading driver of catastrophic health expenditure in low and middle income countries (World Health Organization, 2011), standard treatment courses would impoverish substantial population shares in many settings if purchased at prevailing private prices (Niëns et al., 2010), and survey evidence links household medicine spending directly to financial hardship and weak risk protection (Wagner et al., 2011). Narrative review evidence extends the diagnosis to the supply side, showing how inefficiencies along the pharmaceutical chain, including duplicated distribution tiers, poor demand planning, and high inventory carrying costs, are ultimately priced into the medicines that patients purchase out of pocket (Asiedu & Asiedu, 2023). Any serious strategy for pharmacy-based access must therefore pair delivery innovation with financing reform. The first financing pathway is prepayment and pooling. The global analysis of paths to universal coverage identifies the shift from point of use payment to pooled prepayment as the central structural reform for financial protection (World Health Organization, 2010), and the universal coverage commitment embedded in the Sustainable Development Goals extends explicitly to essential medicines (United Nations, 2015). For the pharmacy sector, the practical implication is the inclusion of outpatient medicines in insurance benefit packages, with accredited or contracted pharmacy networks serving as the dispensing counterparties. Accreditation and financing are mutually reinforcing here: insurers require verifiable quality and record keeping from network pharmacies, which strengthens the commercial case for accreditation, while insurance volume compensates outlets for accepting regulated margins on essential products. The second pathway is targeted subsidy delivered through private channels. The intellectual foundation for this approach was laid in the economic analysis of antimalarial access, which argued that a subsidy applied at the top of the distribution chain could, under competitive conditions, pass www.iiardpub.org through successive markups and reach patients as dramatically lower retail prices, simultaneously crowding out cheaper but ineffective or resistance promoting alternatives (Arrow, Panosian, & Gelband, 2004). The generalizable design lessons extend beyond malaria: pass through depends on competition among distributors and retailers, on communication of recommended retail prices to consumers, and on assured supply of the quality assured product, and subsidy schemes that neglect any of these conditions leak value into channel margins rather than patient savings. The third pathway is strategic purchasing and contracting. Governments and insurers can purchase dispensing services, screening, and chronic disease support from private pharmacy networks rather than attempting to replicate that capacity publicly. The evidence counsels care in how such purchasing is designed. Comparative review of private and public healthcare performance in low- and middle-income countries finds that the private sector is not systematically more efficient or of higher quality, and that its performance varies widely with regulation and market conditions (Basu, Andrews, Kishore, Panjabi, & Stuckler, 2012). Purchasing arrangements therefore need explicit quality conditions, monitoring against dispensing records, and pricing structures that reward appropriate rather than maximal dispensing, echoing the strategic framing of engagement options for the private sector discussed earlier (Montagu & Goodman, 2016). Where these safeguards are present, contracting converts the retail pharmacy network from a source of catastrophic household expenditure into an instrument of financial protection. 7. Integrating Pharmacies into Primary Healthcare Delivery Expanding medicine availability is necessary but not sufficient for strengthening primary healthcare. The larger opportunity lies in integrating pharmacies into the functions of primary care itself: prevention, early detection, management of common and chronic conditions, and navigation of the wider system. The literature identifies several integration pathways. In infectious disease control, accredited drug shops and pharmacies have served as distribution and case management points for priority conditions, extending the reach of national programs into communities that public facilities do not consistently serve (Rutta et al., 2015; Wafula & Goodman, 2010). In non- communicable disease care, pharmacies are positioned to support screening for elevated blood pressure and blood glucose, medication adherence counseling, and refill continuity for long term therapies. Given that chronic disease treatment depends on uninterrupted, affordable supply over years rather than episodic acute purchases, the availability and affordability weaknesses documented for medicines such as insulin translate directly into poor disease control, and pharmacy-level interventions on stocking, pricing, and adherence support are correspondingly consequential (Beran et al., 2016). Conceptual work on equitable access to chronic therapies frames continuity of care as the organizing objective for pharmacy practice in this domain, linking assured stock of long-term medicines, structured refill processes, and affordability safeguards into a single continuity framework rather than treating each as a separate operational concern (Asiedu & Asiedu, 2024a). In public health promotion, community pharmacies in developing Southeast Asian countries have participated in smoking cessation, immunization support, maternal and child health education, and infectious disease campaigns, though typically in pilot or small-scale forms rather than as institutionalized components of national primary care strategy (Hermansyah et al., 2016). The gap between demonstrated capability and institutional recognition is a recurring theme: pharmacies perform primary care functions in practice, yet health policy frameworks, financing arrangements, and information systems rarely acknowledge them as primary care providers. Prevention and self-care constitute a further integration frontier. Pharmacies already serve as major channels for family planning commodities, oral rehydration, micronutrients, and preventive www.iiardpub.org products, and their commercial logic aligns naturally with categories in which patients purchase for anticipated rather than acute needs. Structured engagement can extend this role to immunization support, health education, and the guided self-management of minor conditions, functions that relieve pressure on overstretched clinical facilities while keeping patients within a supervised pathway. The public health case is strongest where these services are delivered against protocols with clear escalation criteria, so that the pharmacy absorbs demand that does not require clinical care and forwards demand that does (Hermansyah et al., 2016; Smith, 2009). Referral is the hinge of safe integration. Because pharmacies attract patients who might otherwise delay or forgo care, they occupy a natural triage position. Training dispensers to recognize danger signs and refer appropriately converts a commercial encounter into a system entry point. Evaluations of accreditation programs report improvements in referral behavior following training and supervision, though sustaining these behaviors requires that referral destinations be functional and that outlets face no financial penalty for referring rather than selling (Wafula & Goodman, 2010; Rutta et al., 2015). The economics of referral repay close attention: an outlet that refers foregoes a sale, and unless accreditation status, program participation, or direct remuneration compensates for that foregone revenue, referral behavior will decay under commercial pressure however thorough the initial training. Programs that have sustained referral behavior have generally succeeded by making the referring outlet a recognized participant in the care pathway rather than an exit point from it, for example through referral documentation that returns to the outlet and through community recognition of accredited status. Finally, information integration remains the least developed pathway. Most private pharmacy transactions in emerging markets leave no trace in national health information systems, depriving planners of demand data and depriving patients of continuity. Digital dispensing records created by e-pharmacy and pharmacy management platforms create, for the first time, a technical basis for linking retail pharmaceutical activity to public health surveillance and to individual care records, provided that governance frameworks for data sharing and privacy are established. 8. Regulation, Quality Assurance, and Policy Design The evidence reviewed above converges on a central lesson: pharmacy-led models deliver public value only when embedded in credible regulatory and quality assurance frameworks. Three design principles stand out. The first is proportionate, enabling regulation. Prohibitionist approaches that criminalize informal sellers without offering a pathway to formality have historically failed, because they ignore the demand that informal sellers meet. Accreditation models succeed by exchanging an expanded, legally protected scope of practice for compliance with training, infrastructure, and record keeping standards, thereby aligning commercial incentives with quality objectives (Rutta et al., 2015). Regulation must also be enforceable at realistic cost; delegating routine inspection to local government structures, as in the Tanzanian model, distributes the enforcement burden in a sustainable way. The strategic menu of prohibiting, constraining, encouraging, or purchasing private health care services offers a useful framing for pharmacy policy; comparative analysis suggests that engagement strategies generally outperform prohibition where state enforcement capacity is limited, which describes most emerging market settings (Montagu & Goodman, 2016). Governance frameworks developed specifically for emerging economy pharmaceutical supply chains extend the regulatory perimeter beyond the outlet to the full chain, integrating supply chain governance, risk management, and sustainability objectives into a single framework for securing access to essential medicines (Eze, Anene, & Akinleye, 2023). At the regional level, cross-border www.iiardpub.org regulatory harmonization models for African pharmaceutical markets address a further structural constraint, since fragmented national registration and inspection regimes raise market entry costs, delay product availability, and thin out supplier competition in smaller markets (Eze, Akinleye, & Anene, 2024). The second is investment in the dispensing workforce. Across systematic reviews, training emerges as the most consistently effective single intervention for improving retail dispensing practice, particularly when reinforced by supervision and peer networks (Smith, 2009; Wafula & Goodman, 2010; Miller & Goodman, 2016). Workforce policy should encompass not only pharmacists but the much larger cadre of dispensers and shop attendants who conduct the majority of patient interactions in emerging markets. The third is attention to incentive structures. Retail outlets earn revenue from selling products, which can bias behavior toward overselling, brand substitution, or dispensing without prescription (Goel et al., 1996; Miller & Goodman, 2016). Policy instruments that decouple outlet income from unnecessary sales, including remuneration for services such as screening and counseling, margin regulation on essential medicines paired with volume growth through insurance coverage, and reputational mechanisms such as public accreditation branding, are needed to make quality commercially rational. Sound policy design also requires an accurate empirical picture of the market being regulated. Foundational analysis of private health care provision in developing countries demonstrated both its scale and its heterogeneity, and warned that policy built on stylized assumptions about 'the private sector' would misfire against the layered reality of pharmacies, drug sellers, and informal providers (Hanson & Berman, 1998). Building on that evidence, the policy literature has organized the available instruments into complementary families, spanning information and education, regulation and enforcement, financing incentives, purchasing and contracting, and support for professional self-regulation, and has argued that low income countries obtain the best results by combining instruments matched to their enforcement capacity rather than relying on any single tool (Mills, Brugha, Hanson, & McPake, 2002). The pharmacy-led models reviewed in this paper can be read as applied combinations of exactly these instrument families: accreditation joins regulation with information and incentives, franchising joins self-regulation with purchasing power, and digital platforms join information with financing. Underlying all three principles is the health systems insight that access interventions interact (Bigdeli et al., 2013). The concept of pharmaceutical systems strengthening captures this requirement, defining the pharmaceutical system as the interconnected structures, people, processes, and resources that ensure access to and appropriate use of quality medicines, and directing policy attention to system wide capability rather than isolated interventions (Hafner, Walkowiak, Lee, & Aboagye-Nyame, 2017). Accreditation without supply chain reform yields compliant shelves that are empty; supply chain reform without affordability measures yields stocked shelves that patients cannot pay for; affordability measures without quality assurance yield cheap products of uncertain value. Policy design for pharmacy-led access must therefore be deliberately multi-component. 9. Discussion Taken together, the advances reviewed in this paper describe a maturing field. Three decades ago, the scholarly literature treated retail pharmacies in developing countries principally as a problem of irrational drug use to be corrected (Goel et al., 1996). Today, the frame has shifted decisively toward engagement: pharmacies are increasingly understood as infrastructure, a distributed network of trusted access points whose upgrading offers one of the highest leverage opportunities available for strengthening primary healthcare in emerging markets. Accreditation programs have www.iiardpub.org demonstrated national scalability; franchise and chain models have demonstrated that standardization and commercial sustainability can coexist; digital platforms are attacking the fragmentation and data blindness that have historically crippled pharmaceutical distribution; and expanded scopes of practice are converting dispensing points into primary care contacts. Nonetheless, the evidence base counsels’ realism on several fronts. First, evaluation quality is uneven. Many studies of pharmacy interventions are small, short in duration, reliant on simulated client or self-report methods, and rarely powered to detect health outcomes rather than process improvements (Smith, 2009; Wafula & Goodman, 2010; Miller & Goodman, 2016). The strongest causal evidence on availability gains comes from public sector supply chain experiments rather than from retail interventions themselves (Vledder et al., 2019), and extrapolation across sectors requires caution. Second, equity effects deserve closer scrutiny. Pharmacy-led models are strongest where purchasing power exists; the poorest and most remote populations may remain dependent on the public sector or on informal sellers outside the reach of accreditation and digital platforms. Without complementary financing reforms that reduce out of pocket exposure, availability gains may not translate into utilization gains for the poor (World Health Organization, 2011; Cameron et al., 2009). The distributional question should be asked of every model reviewed here: whose availability improves, whose prices fall, and whose access is left unchanged? Accreditation reaches the communities where drug shops already operate, which favors rural inclusion, while chains and digital platforms concentrate first in urban markets, which favors the already better served; targeted subsidies reach whoever purchases the subsidized product, which favors users of private channels over those with no cash income at all (Peters et al., 2008; Niëns et al., 2010). An equity conscious strategy sequences these instruments deliberately rather than assuming that aggregate availability gains diffuse evenly. Third, governance risks accompany consolidation. As chains and platforms concentrate market share, questions of pricing power, data ownership, and regulatory capture arise, and emerging market regulators will need capabilities that most currently lack. Measurement deserves particular attention as the field matures. The standardized survey methodology that produced the foundational cross-country evidence on prices and availability demonstrated the value of comparable measurement for policy accountability (Cameron et al., 2009), yet most emerging markets still lack routine monitoring of availability, price, and dispensing quality in the retail sector. The digitization of pharmacy transactions creates an opportunity to move from periodic surveys to continuous measurement, since electronic dispensing and purchasing records can yield near real time indicators of stock levels, price dispersion, and product mix. Realizing that opportunity requires governance arrangements under which commercial platform data can be used for public monitoring without compromising competitive or personal information, an institutional design problem that remains largely unsolved. Resilience is a further consideration that the events of 2020 have made impossible to ignore. Global supply disruptions expose the dependence of national pharmaceutical availability on international manufacturing and logistics chains whose fragilities were diagnosed well before that emergency (Yadav, 2015), and quality risks intensify when scarcity invites opportunistic entry of substandard and falsified products into stressed markets (World Health Organization, 2017). A dispersed, digitally connected retail pharmacy network is, in principle, a resilience asset: it distributes inventory across thousands of points, maintains service when individual facilities close, and generates the consumption data needed to manage allocation under scarcity. But that potential is realized only where the upstream reforms discussed in Section 4, pooled procurement, channel integrity, and data visibility, are already in place. www.iiardpub.org The research agenda that follows from these observations includes rigorous, longer term evaluations of accreditation and platform models with health outcome endpoints; costing and sustainability studies of expanded pharmacy services; analyses of the distributional incidence of pharmacy-led availability gains; and design research on integrating private dispensing data into national health information systems under sound governance. For policymakers, the immediate priorities are clearer: recognize pharmacies formally within primary healthcare policy, invest in dispenser training and supervision at scale, enable pooled procurement and quality assured distribution channels, and construct remuneration mechanisms that reward service quality rather than sales volume alone. 10. Conclusion Pharmacy-led delivery and access models have moved from the margins of health policy to a central position in strategies for strengthening primary healthcare and expanding medicine availability in emerging markets. The retail pharmaceutical layer possesses attributes that public systems in these settings chronically lack: proximity, extended hours, patient trust, and commercial resilience. The advances reviewed in this paper show that these attributes can be harnessed for public purposes. Accreditation and upgrading programs convert informal sellers into regulated providers; franchising, chains, and digital aggregation bring standardization, lower acquisition costs, and supply reliability to fragmented markets; and expanded, well governed scopes of practice turn dispensing encounters into genuine primary care contacts encompassing screening, counseling, adherence support, and referral. The evidence equally shows that none of these gains is automatic. They depend on credible and proportionate regulation, sustained investment in the dispensing workforce, supply chains built on consumption data and channel integrity, and incentive structures that make quality profitable. They also depend on complementary financing measures, since availability without affordability leaves the poorest households behind. The appropriate conclusion is neither uncritical enthusiasm for private pharmacy channels nor reflexive suspicion of them, but deliberate system design that assigns pharmacies a formal, accountable role within the primary healthcare architecture. Where that design work is done well, the corner pharmacy ceases to be a gap in the health system and becomes one of its strongest assets. The direction of travel for the coming decade follows from this analysis. Emerging market health systems that formally recognize their retail pharmaceutical layer, invest in its workforce, connect it to data driven and quality assured supply chains, and finance its services through pooling and strategic purchasing will convert an existing, self-sustaining network into the most geographically extensive tier of their primary healthcare systems. Those that continue to treat pharmacies as peripheral commercial actors will keep paying for the resulting fragmentation in stockouts, catastrophic household expenditure, and missed opportunities for prevention and early care. The choice between these paths is a matter of policy design, and the accumulated experience reviewed in this paper indicates that the tools for choosing well are already available. www.iiardpub.org References Arrow, K. J., Panosian, C., & Gelband, H. (Eds.). (2004). Saving lives, buying time: Economics of malaria drugs in an age of resistance. Washington, DC: The National Academies Press. Asiedu, C. S. (2025). A lean process-improvement framework for pharmaceutical inventory and distribution management. , 10(12), 225-252. Asiedu, C. S. (2026). Toward a systems-level framework for healthcare access, affordability, and supply chain resilience. , 11(5), 128-156. Asiedu, C. S., & Asiedu, A. A. (2022). Last-mile drug distribution to underserved communities: A review of barriers and intervention models. Gyanshauryam, International Scientific Refereed Research Journal, 5(6), 439-466. Asiedu, C. S., & Asiedu, A. A. (2023). Pharmaceutical supply chain inefficiencies and medication affordability in resource-constrained health systems: A narrative review. International Journal of Health and Pharmaceutical Research, 8(4), 192-222. Asiedu, C. S., & Asiedu, A. A. (2024a). Equitable access to chronic therapies in hospital pharmacy settings: A conceptual framework for continuity of care. International Journal of Medical Evaluation and Physical Report, 8(6), 274-298. Asiedu, C. S., & Asiedu, A. A. (2024b). Reconceptualizing quality assurance in pharmaceutical manufacturing as a determinant of supply reliability. International Journal of Health and Pharmaceutical Research, 9(5), 148-173. Basu, S., Andrews, J., Kishore, S., Panjabi, R., & Stuckler, D. (2012). Comparative performance of private and public healthcare systems in low- and middle-income countries: A systematic review. PLoS Medicine, 9(6), e1001244. Beran, D., Ewen, M., & Laing, R. (2016). Constraints and challenges in access to insulin: A global perspective. The Lancet Diabetes & Endocrinology, 4(3), 275-285. Beyeler, N., Liu, J., & Sieverding, M. (2015). A systematic review of the role of proprietary and patent medicine vendors in healthcare provision in Nigeria. PLoS ONE, 10(1), e0117165. Bigdeli, M., Jacobs, B., Tomson, G., Laing, R., Ghaffar, A., Dujardin, B., & Van Damme, W. (2013). Access to medicines from a health system perspective. Health Policy and Planning, 28(7), 692-704. Bloom, G., Standing, H., Lucas, H., Bhuiya, A., Oladepo, O., & Peters, D. H. (2011). Making health markets work better for poor people: The case of informal providers. Health Policy and Planning, 26(Suppl. 1), i45-i52. Brieger, W. R., Osamor, P. E., Salami, K. K., Oladepo, O., & Otusanya, S. A. (2004). Interactions between patent medicine vendors and customers in urban and rural Nigeria. Health Policy and Planning, 19(3), 177-182. Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., & Laing, R. (2009). Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. The Lancet, 373(9659), 240-249. Chuc, N. T., Larsson, M., Do, N. T., Diwan, V. K., Falkenberg, T., & Tomson, G. (2002). Improving private pharmacy practice: A multi-intervention experiment in Hanoi, Vietnam. Journal of Clinical Epidemiology, 55(11), 1148-1155. Ewen, M., Zweekhorst, M., Regeer, B., & Laing, R. (2017). Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS ONE, 12(2), e0171284. www.iiardpub.org Eze, F. I., Akinleye, O. K., & Anene, U. N. (2024). Development of a cross-border regulatory harmonization model for African pharmaceutical markets: The ARCH-Model framework. , 9(5), 148-186. Eze, F. I., Anene, U. N., & Akinleye, O. K. (2022). Creation of a drug shortage early warning and regulatory response model for essential medicines in global health systems. Research Journal of Pure Science and Technology, 5(1), 57-95. Eze, F. I., Anene, U. N., & Akinleye, O. K. (2023). Pharmaceutical supply chain governance, environmental risk management, and sustainable access to essential medicines in emerging economies: The PSCG-ERM framework. International Journal of Health and Pharmaceutical Research, 8(4), 192-241. Frost, L. J., & Reich, M. R. (2008). Access: How do good health technologies get to poor people in poor countries? Cambridge, MA: Harvard Center for Population and Development Studies. Goel, P., Ross-Degnan, D., Berman, P., & Soumerai, S. (1996). Retail pharmacies in developing countries: A behavior and intervention framework. Social Science & Medicine, 42(8), 1155-1161. Goodman, C., Brieger, W., Unwin, A., Mills, A., Meek, S., & Greer, G. (2007). Medicine sellers and malaria treatment in sub-Saharan Africa: What do they do and how can their practice be improved? American Journal of Tropical Medicine and Hygiene, 77(6, Suppl.), 203- 218. Hafner, T., Walkowiak, H., Lee, D., & Aboagye-Nyame, F. (2017). Defining pharmaceutical systems strengthening: Concepts to guide practice, research and evaluation. Health Policy and Planning, 32(4), 572-584. Hanson, K., & Berman, P. (1998). Private health care provision in developing countries: A preliminary analysis of levels and composition. Health Policy and Planning, 13(3), 195- 211. Hermansyah, A., Sainsbury, E., & Krass, I. (2016). Community pharmacy and emerging public health initiatives in developing Southeast Asian countries: A systematic review. Health & Social Care in the Community, 24(5), e11-e22. Kaplan, W. A., Ritz, L. S., Vitello, M., & Wirtz, V. J. (2012). Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000 to 2010. Health Policy, 106(3), 211-224. Laing, R., Waning, B., Gray, A., Ford, N., & 't Hoen, E. (2003). 25 years of the WHO essential medicines lists: Progress and challenges. The Lancet, 361(9370), 1723-1729. Mackintosh, M., Channon, A., Karan, A., Selvaraj, S., Cavagnero, E., & Zhao, H. (2016). What is the private sector? Understanding private provision in the health systems of low-income and middle-income countries. The Lancet, 388(10044), 596-605. Miller, R., & Goodman, C. (2016). Performance of retail pharmacies in low- and middle-income Asian settings: A systematic review. Health Policy and Planning, 31(7), 940-953. Mills, A., Brugha, R., Hanson, K., & McPake, B. (2002). What can be done about the private health sector in low-income countries? Bulletin of the World Health Organization, 80(4), 325-330. Montagu, D., & Goodman, C. (2016). Prohibit, constrain, encourage, or purchase: How should we engage with the private health-care sector? The Lancet, 388(10044), 613-621. Newton, P. N., Green, M. D., Fernandez, F. M., Day, N. P. J., & White, N. J. (2006). Counterfeit anti-infective drugs. The Lancet Infectious Diseases, 6(9), 602-613. www.iiardpub.org Niens, L. M., Cameron, A., Van de Poel, E., Ewen, M., Brouwer, W. B. F., & Laing, R. (2010). Quantifying the impoverishing effects of purchasing medicines: A cross-country comparison of the affordability of medicines in the developing world. PLoS Medicine, 7(8), e1000333. Ozawa, S., Evans, D. R., Bessias, S., Haynie, D. G., Yemeke, T. T., Laing, S. K., & Herrington, J. E. (2018). Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries: A systematic review and meta-analysis. JAMA Network Open, 1(4), e181662. Ozawa, S., Shankar, R., Leopold, C., & Orubu, S. (2019). Access to medicines through health systems in low- and middle-income countries. Health Policy and Planning, 34(Suppl. 3), iii1-iii3. Penchansky, R., & Thomas, J. W. (1981). The concept of access: Definition and relationship to consumer satisfaction. Medical Care, 19(2), 127-140. Peters, D. H., Garg, A., Bloom, G., Walker, D. G., Brieger, W. R., & Rahman, M. H. (2008). Poverty and access to health care in developing countries. Annals of the New York Academy of Sciences, 1136, 161-171. Rutta, E., Liana, J., Embrey, M., Johnson, K., Kimatta, S., Valimba, R., Lieber, R., Shekalaghe, E., & Sillo, H. (2015). Accrediting retail drug shops to strengthen Tanzania's public health system: An ADDO case study. Journal of Pharmaceutical Policy and Practice, 8, 23. Shah, N. M., Brieger, W. R., & Peters, D. H. (2011). Can interventions improve health services from informal private providers in low and middle-income countries? A comprehensive review of the literature. Health Policy and Planning, 26(4), 275-287. Smith, F. (2009). The quality of private pharmacy services in low and middle-income countries: A systematic review. Pharmacy World & Science, 31(3), 351-361. Sudhinaraset, M., Ingram, M., Lofthouse, H. K., & Montagu, D. (2013). What is the role of informal healthcare providers in developing countries? A systematic review. PLoS ONE, 8(2), e54978. United Nations. (2015). Transforming our world: The 2030 Agenda for Sustainable Development (A/RES/70/1). New York, NY: United Nations. Vledder, M., Friedman, J., Sjoblom, M., Brown, T., & Yadav, P. (2019). Improving supply chain for essential drugs in low-income countries: Results from a large scale randomized experiment in Zambia. Health Systems & Reform, 5(2), 158-177. Wafula, F. N., & Goodman, C. A. (2010). Are interventions for improving the quality of services provided by specialized drug shops effective in sub-Saharan Africa? A systematic review of the literature. International Journal for Quality in Health Care, 22(4), 316-323. Wafula, F. N., Miriti, E. M., & Goodman, C. A. (2012). Examining characteristics, knowledge and regulatory practices of specialized drug shops in Sub-Saharan Africa: A systematic review of the literature. BMC Health Services Research, 12, 223. Wagner, A. K., Graves, A. J., Reiss, S. K., LeCates, R., Zhang, F., & Ross-Degnan, D. (2011). Access to care and medicines, burden of health care expenditures, and risk protection: Results from the World Health Survey. Health Policy, 100(2-3), 151-158. World Health Organization. (2010). The world health report. Health systems financing: The path to universal coverage. Geneva: World Health Organization. World Health Organization. (2011). The world medicines situation 2011. Geneva: World Health Organization. www.iiardpub.org World Health Organization. (2017). A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization. Yadav, P. (2015). Health product supply chains in developing countries: Diagnosis of the root causes of underperformance and an agenda for reform. Health Systems & Reform, 1(2), 142-154.